奥扎格雷钠联合低分子肝素治疗急性脑梗死的临床研究

目的观察奥扎格雷钠联合低分子肝素治疗急性脑梗死的疗效。方法选取我院从2009年6月至2012年6月所收治的急性脑梗死患者100例作为临床研究对象,将所有患者随机分为治疗组和对照组两组,两组患者均进行降压、吸氧、调脂等常规治疗。治疗组应用奥扎格雷钠针联合低分子肝素治疗,对照组单纯采用奥扎格雷钠针治疗。采用Ess评分在治疗后3、7、14、30d各进行一次评价,同时采用Bathel指数对患者进行评定。结果治疗组在治疗后3、7、14、30d的Ess评分均高于对照组,差异有统计学意义(P<0.05)。同时Bathel指数也是治疗组显著高于对照组,差异有统计学意义(P<0.05)。结论奥扎格雷钠联合低分子肝素在对急性脑梗死中效果显著,两组有协同抗凝和抗血栓的作用,可以提高临床治疗效果,且使用安全方便,值得在临床治疗当中推广应用。

The Effect of Ozagrel Sodium Combined LMWHC in the Treatment of Acute Cerebral Infarction

Objective To explore the effect of Ozagrel Sodium combined LMWHC in the treatment of acute cerebral infarction. Methods 100cases of patients with acute cerebral infarction admitted into our hospital from June 2009 to June 2012 were selected as objects. They were randomLy divided into treatment group and control group. Antihypertensive, oxygen therapy and lipid therapy were given to two groups. Ozagrel Sodium combined LMWHC was given to treatment group on the basic of conventional treatment. ESS was used to evaluate the effect by 3days, 7days, 14days and 30days after therapy and Bathel index was taken to assess the effect. Results The ESS sore of treatment group by 3,7,14 and 30days after therapy was higher than control group, the difference was statistically significant （P〈0.05）. The Bathel index of treatment group was higher than control and the difference was statistically significant （P〈0.05）. Conclusions Ozagrel Sodium combined LMWHC has a great effect on acute cerebral infarction. It can improve the clinic effect. It is safely and convent. So it is worthy to be widely spread in clinic.